Latest California Healthline Stories
Although nearly 40% of Americans 60 and older are obese, Medicare doesn’t cover weight loss medications. Meanwhile, studies haven’t thoroughly examined new drugs’ impact on older adults.
The “Diabetes Belt,” as defined by the Centers for Disease Control and Prevention, comprises 644 mostly Southern counties where diabetes rates are high. Of those counties, KFF Health News and NPR found, more than half also have high levels of medical debt.
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
La competencia para hacerse con un mercado que podría valer $100.000 millones al año, solo para los fabricantes de medicamentos, ha desencadenado una ola de publicidad que preocupa a las autoridades sanitarias y médicos de todo el mundo.
The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
Montana is one of several states considering expanding coverage of continuous glucose monitors, but insurance companies and some providers argue that not all people with diabetes need them.
California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Fresh produce prescription programs are getting a boost in Montana as a way of helping people with chronic conditions such as diabetes and high blood pressure. The approach may be a model for other rural states to promote healthy eating in food deserts.
Civica está desarrollando tres tipos de insulina genérica, conocida como biosimilar, que estarán disponibles tanto en viales como en plumas inyectables, a un costo de entre $30 y $55.
Gov. Gavin Newsom, who blasted pharmaceutical companies for gouging Californians, is moving ahead with state-branded insulin. He’s also eyeing other generic drugs.